Kyverna presents miv-cel data showing sustained mobility improvements in stiff person syndrome at one year
KYTX•Kyverna reported that 92% of patients in a 26-patient registrational trial remained off chronic stiff person syndrome immunotherapies at one year, with median timed 25-foot walk improving 49% from baseline. The company plans to complete miv-cel’s rolling biologics license application in Q4 2026, targeting a potential 2027 launch.
1. One-year trial results
Kyverna said its 26-patient registrational trial met its primary endpoint, with a 46% median reduction in timed 25-foot walk at 16 weeks. At one year, 92% of patients remained off chronic stiff person syndrome immunotherapies, and median timed 25-foot walk improved 49% from baseline.
2. Regulatory and trial plans
Kyverna plans to complete miv-cel’s rolling biologics license application in Q4 2026, targeting a potential 2027 launch. The company expects enrollment in its phase 3 generalized myasthenia gravis trial to finish by mid-2027.
